A recent clinical trial is set to explore Liquid IV’s RECOVER proprietary post-workout supplement as a potential aid in enhancing muscle recovery and overall physical performance following exercise. With muscle recovery being a priority for professionals and recreational athletes alike, the study seeks to provide evidence-based insights on RECOVER’s effectiveness when compared to a control placebo. The trial is sponsored by the Applied Science & Performance Institute and remains categorized as “not yet recruiting.” Expected to launch in the near future, this investigation could have meaningful implications for healthcare professionals, regulatory bodies, and athletic organizations.
What is the focus of the study?
The clinical trial aims to test the efficacy of Liquid IV’s RECOVER post-workout supplement in improving muscle recovery outcomes. Participants in the study will undergo a randomized crossover design to compare the proprietary recovery formulation against a control placebo. The research targets critical aspects of post-exercise recovery, such as muscle damage, strength recovery, perceived muscle soreness, and overall physical performance.
This scientific inquiry aligns with the growing demand for innovations that support faster recovery times and improved athletic performance. The findings may also contribute to regulatory evaluations and pave the way for more standardized measures of supplement efficiency in sports and rehabilitation contexts.
Why is this trial important?
Muscle degeneration and delayed recovery are common challenges faced by athletes and active individuals. By investigating the specific benefits of Liquid IV’s formulation, this trial endeavors to fill existing gaps in evidence, guiding healthcare providers and regulatory committees in formulating recommendations for dietary supplements targeting recovery.
What are the interventions?
Two interventions will be employed in this study involving RECOVER:
- Proprietary Post-Workout Recovery Supplement: An innovation from Liquid IV, designed to accelerate recovery after intense physical activity.
- Control Placebo: A baseline comparison to isolate the specific impacts of the proprietary supplement.
Researchers will monitor participants across various health indicators, analyzing their muscle recovery trajectory post-exercise.
When will participant recruitment begin?
The trial is currently designated as “not yet recruiting,” indicating that participant enrollment has not started as of the publication date, November 7, 2025. Once active, clinical sites will employ rigorous selection and monitoring criteria to ensure scientifically valid results.
Sponsorship: Led by the Applied Science & Performance Institute, the study highlights the organization’s commitment to advancing scientific research in performance optimization and rehabilitation.
FAQ
- What type of study design is being used?
A randomized crossover study design will compare the effectiveness of the supplement against a placebo. - Who can participate?
Eligibility criteria will be established by the trial administrators upon opening for recruitment, likely involving individuals engaged in regular physical activity. - What outcomes will be measured?
The study will evaluate muscle damage, strength recovery, perceived soreness, perceived recovery, and overall physical performance. - When will the results be available?
Results can be expected after the trial concludes and data undergoes rigorous analysis, though specific timelines remain subject to the trial’s progression.
Key implications
The imminent launch of this clinical trial underscores the importance of evidence-based evaluation in sports nutrition and recovery. Healthcare professionals, athletic trainers, and regulatory staff should monitor developments closely for insights that could inform future recommendations and product validations.
Continued collaboration between manufacturers, researchers, and regulatory bodies remains pivotal to promoting scientifically-backed health solutions.
Disclaimer
The information provided in this content is intended for healthcare professionals, regulatory personnel, and others involved in the clinical sciences. This article does not constitute legal advice.
Official clinical trial listing
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07224867?term=medical+device